Rapport Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.36B
- P/E (TTM)
- –
- Dividend yield
- –
About Rapport Therapeutics
Pharmaceutical Preparations, SIC 2834
Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops small molecule precision medicines for patients with neurological and psychiatric disorders. The company utilizes a receptor-associated protein platform to target specific neuronal receptor assemblies. Its lead product candidate, RAP-219, is an AMPA receptor negative allosteric modulator in development for drug-resistant focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. In addition, the firm advances discovery-stage nicotinic acetylcholine receptor programs, including RAP-641 for chronic pain and migraine, alongside therapies for hearing and vestibular disorders. Its patient population comprises individuals affected by serious central nervous system and sensory conditions.
The company maintains its corporate headquarters in Boston, Massachusetts, and holds laboratory and office facilities in San Diego, California. Its operational presence and research efforts are located within the United States. As a development-stage entity, it operates in the biopharmaceutical sector without commercialized products.
Summary of the business section of Rapport Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Rapport Therapeutics, Inc.
- Headquarters
- Boston, MA
- Address
- 99 High Street, Suite 2100 02110
- Phone
- (857) 321-8020
- Website
- rapportrx.com
- Employees
- 84, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- RAPP
- Exchange
- Nasdaq
- IPO date
- Jun 7, 2024
- Shares outstanding
- 48M, Aug 3, 2026
- Public float
- $275.84M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2012593
- CUSIP
- 75383L102
- ISIN
- US75383L1026
- EIN
- 88-0724208
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Abraham Ceesay | Chief Executive Officer, Director | 559,268 |
| Krishnaswamy Yeleswaram | Chief Development Officer | 212,063 |
| Cheryl Gault | Chief Operating Officer | 154,222 |
| David Bredt | Chief Scientific Officer | 393,075 |
| Jeffrey Sevigny | Chief Medical Officer | – |
| Troy A. Ignelzi | Chief Financial Officer | 10,000 |
| Ramiro Sanchez | Director | – |
| Wendy B. Young | Director | 9,500 |
| Steven M. Paul | Director | 519,308 |
| Paul M. Silva | Director | – |
| James Healy | Director | 1,988,308 |
| Reid M. Huber | Director | 20,400 |
| Robert J. Perez | Director | – |
| John Maraganore | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 84 full-time employees, and approximately 33 of our employees have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 7, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 4, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |